placebo in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results NIH NIAID ACTT-1, 2020 (REV) 1.37 [0.97; 1.93]
1.37 [0.97 ; 1.93 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,062 NA not evaluable deathsdetailed results NIH NIAID ACTT-1, 2020 (REV) 1.82 [1.20; 2.76]
1.82 [1.20 ; 2.76 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,062 NA not evaluable deaths (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 (REV) 1.82 [1.20; 2.76]
1.82 [1.20 ; 2.76 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,062 NA not evaluable clinical improvementdetailed results NIH NIAID ACTT-1, 2020 (REV) 0.78 [0.67; 0.89]
0.78 [0.67 ; 0.89 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,062 NA not evaluable clinical improvement (28-day)detailed results NIH NIAID ACTT-1, 2020 (REV) 0.74 [0.57; 0.97]
0.74 [0.57 ; 0.97 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,062 NA not evaluable clinical improvement (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 (REV) 0.78 [0.67; 0.89]
0.78 [0.67 ; 0.89 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,062 NA not evaluable serious adverse eventsdetailed results NIH NIAID ACTT-1, 2020 (REV) 1.39 [1.04; 1.84]
1.39 [1.04 ; 1.84 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,063 NA not evaluable deep vein thrombosisdetailed results NIH NIAID ACTT-1, 2020 (REV) 1.56 [0.55; 4.43]
1.56 [0.55 ; 4.43 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,063 NA not evaluable elevated liver enzymesdetailed results NIH NIAID ACTT-1, 2020 (REV) 1.49 [0.85; 2.61]
1.49 [0.85 ; 2.61 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,063 NA not evaluable hyperbilirubinemiadetailed results NIH NIAID ACTT-1, 2020 (REV) 1.19 [0.43; 3.30]
1.19 [0.43 ; 3.30 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,063 NA not evaluable pulmonary embolismdetailed results NIH NIAID ACTT-1, 2020 (REV) 1.04 [0.21; 5.16]
1.04 [0.21 ; 5.16 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,063 NA not evaluable renal impairmentdetailed results NIH NIAID ACTT-1, 2020 (REV) 0.98 [0.62; 1.56]
0.98 [0.62 ; 1.56 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,063 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 07:57 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 94
- treatments: 650
- roots T: 650